Accessibility Menu
Cogstate logo

Cogstate(ASX) CGS

Market CapA$516.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)+540%
5 Year+95%
1 Year+80%
1 Month+24%
A$3.08
+1.32%
+0.04Today
Cogstate last closing stock price
MetricPriceDate
Last closeAUD 3.082026-09-02
Cogstate stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.65%AUD 3.062026-08-26
1 month+24.32%AUD 2.482026-08-03
3 month+25.32%AUD 2.462026-06-04
Year to date+38.08%AUD 2.232025-12-31
1 year+79.86%AUD 1.712025-09-02
3 year+104.91%AUD 1.502023-09-01
5 year+94.79%AUD 1.582021-09-03
Since inception+539.9%AUD 0.482004-02-16

Cogstate Financials at a Glance

Market Cap

A$516.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$112.54M

Net Income (TTM)

$22.20M

EPS (TTM)

A$0.10

P/E Ratio

29.86

Dividend

A$0.04

Beta (Volatility)

-0.06 (Low)

Price

A$3.08

Volume

0

Open

A$3.04

Previous Close

A$3.08

Daily Range

A$2.99 - A$3.10

52-Week Range

A$1.69 - A$3.23

Estimated Earnings Date

Feb 24, 2027

CGS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cogstate

Cogstate Limited is a Melbourne-based neuroscience technology company that specializes in computerized cognitive assessments and digital solutions for clinical outcome evaluations. Established in 1999, the company serves pharmaceutical and biotechnology clients through its Clinical Trials segment and offers cognitive testing solutions in its Healthcare segment.

Products and Services
  • Computerized cognitive assessments for clinical trials
  • Cognigram system for early identification of cognitive decline
  • Comprehensive project and data management services
Growth Outlook
  • Participation in approximately 1,800 academic research initiatives
  • Increasing demand for cognitive assessment solutions in healthcare
  • Expansion of services in the pharmaceutical sector driving revenue growth
Financial Highlights
  • Recent quarterly revenue of 32.34 million USD, a significant increase
  • Trailing twelve months (TTM) net income margin of 20.26%
  • Strong cash position with 34.77 million USD in cash and equivalents
Cogstate Limited operates in a niche market with a focus on cognitive health, which is increasingly relevant in both clinical and healthcare settings. The company's innovative products and services are designed to meet the growing needs of researchers and healthcare providers. Recent financial performance indicates a robust revenue stream and a healthy net income margin, reflecting effective management and operational efficiency. The strong cash position further supports potential growth initiatives and strategic investments. As the demand for cognitive assessment tools continues to rise, Cogstate is well-positioned to capitalize on these opportunities, making it an intriguing option for investors interested in the healthcare technology sector.
AI Generated • Aug 20, 2026

Industry

Health Care Technology

Sector

Health Care

Employees

410

CEO

Bradley John O'Connor

Website

www.cogstate.com

Headquarters

Melbourne, VIC 3000, AU

CGS Financials

Key Financial Metrics (TTM)

Gross Margin

33.72%

Operating Margin

20.54%

Net Income Margin

20.26%

Return on Equity

21.61%

Return on Capital

21.08%

Return on Assets

15.22%

Earnings Yield

3.35%

Dividend Yield

1.32%

Payout Ratio

17.92%

Stock Overview

Market Cap

A$516.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

169.92M

Volume

0

Avg. Volume

425.97K

Financials (TTM)

Gross Profit

$46.60M

Operating Income

$26.72M

EBITDA

$32.13M

Operating Cash Flow

$21.63M

Capital Expenditure

-$801.51K

Free Cash Flow

$20.83M

Cash & ST Invst.

$34.77M

Total Debt

$359.03K

Cogstate Performance Analysis

Cogstate annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30USD 60,132,082-3.0%
20242024-06-30USD 66,264,00410.2%
20252025-06-30USD 81,977,01923.7%
20262026-06-30USD 86,457,9265.5%
Cogstate sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-6.8%
Q42025-06-3025.3%
Q22025-12-31-12.5%
Q42026-06-3023.2%
Cogstate annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30USD 0.03-48.6%
20242024-06-30USD 0.0559.5%
20252025-06-30USD 0.0987.5%
20262026-06-30USD 0.1010.0%
Cogstate sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3112.0%
Q42025-06-3065.2%
Q22025-12-31-29.5%
Q42026-06-3056.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

$32.34M

+25.8%

Gross Profit

$12.49M

+30.9%

Gross Margin

38.64%

N/A

Market Cap

A$516.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$3.23M

N/A

Employees

160

N/A

Net Income

$7.26M

+110.7%

EBITDA

$9.81M

+86.6%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

$34.77M

+73.1%

Total Debt

$359.03K

-46.6%

Accounts Receivable

$22.44M

+233.8%

Inventory

$0.00

N/A

Long Term Debt

$240.75K

-47.1%

Short Term Debt

$118.28K

-45.7%

Return on Assets

15.22%

N/A

Return on Invested Capital

19.61%

N/A

Free Cash Flow

$6.20M

+3.3%

Operating Cash Flow

$6.32M

+2.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ACL.AXAustralian Clinical Labs Limited
A$2.71+0.09%
OCA.AXOceania Healthcare Limited
A$0.66+0.00%
IMR.AXImricor Medical Systems, Inc.
A$1.84-3.67%
CUV.AXClinuvel Pharmaceuticals Limited
A$8.36+1.46%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$224.41+0.03%
PCGPG&E
$13.33-0.05%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.37+0.00%
NUNu Holdings
$15.40+0.07%

Questions About CGS

What is the current price of Cogstate?

Cogstate is trading at A$3.08 per share.

What is the 52-week range for Cogstate?

Over the past 52 weeks, Cogstate has traded between A$1.69 and A$3.23.

How much debt does Cogstate have?

As of the most recent reporting period, Cogstate reported total debt of $518.45K.

How much cash does Cogstate have on hand?

Cogstate reported $50.20M in cash and cash equivalents in its most recent financial results.

What is Cogstate’s dividend yield?

Cogstate currently has a dividend yield of 1.32%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services